LONG-TERM EFFICACY AND SAFETY OF FOSAMPRENAVIR IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PEDIATRIC PATIENTS

• DOI: 10.1097/inf.0b013e3181d285ac
• Publication Date: 2010-03-18T09:38:32Z
• Authors: Claudia Palladino; Verónica Briz; Sergio Negre Poli...; Laura Fernandez S...; M Isabel de José; M Isabel González...; David Moreno; Juan A. León Leal; M José Mellado; Santiago J. de Ory; José T. Ramos; M Ángeles Muñoz-F...
• Keywords: Ritonavir

Fosamprenavir (FPV) efficacy in human immunodeficiency virus (HIV)-infected pediatric patients is still being evaluated ongoing clinical trials. The long-term and safety of FPV boosted with ritonavir (FPV/r) was 20 antiretroviral-naive antiretroviral-experienced HIV-vertically infected patients. Analyses CD4(+) T-cells, HIV-ribonucleic acid (RNA), status were performed during a median 180 weeks. Initially, HIV-RNA 4.6 log(10) naive 4.4 pretreated Median T-cell 17% 31%, respectively. After FPV/r treatment, 18 achieved undetectable 4 experienced adverse events. To date, treatment has shown sustained antiviral response immunologic improvement our